{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:29:00Z","timestamp":1791595740250,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1684\/bdc.2013.1840","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:02:13Z","timestamp":1565726533000},"page":"1199-1206","source":"Crossref","is-referenced-by-count":13,"title":["Agents ciblant le remodelage osseux : les bisphosphonates"],"prefix":"10.1016","volume":"100","author":[{"given":"Fran\u00e7oise","family":"Debiais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2013.1840_bib0005","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Rodman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2013.1840_bib0010","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1684\/bdc.2013.1840_bib0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates. An update on mechanisms of action and how relate to clinical efficacy?","volume":"1117","author":"Russell","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1684\/bdc.2013.1840_bib0020","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.rhum.2008.01.003","article-title":"Bisphosphonates et traitements innovants de l\u2019ost\u00e9olyse tumorale","volume":"75","author":"Debiais","year":"2008","journal-title":"Rev Rhum"},{"key":"10.1684\/bdc.2013.1840_bib0025","first-page":"CD003474","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"2","author":"Wong","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1684\/bdc.2013.1840_bib0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1684\/bdc.2013.1840_bib0035","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2013.1840_bib0040","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Van Poznack","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1840_bib0045","unstructured":"NCCN clinical practice guidelines in oncology in breast cancer. Version 3. 2013. http:\/\/www.NCCN.org"},{"key":"10.1684\/bdc.2013.1840_bib0050","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2013.1840_bib0055","unstructured":"NCCN clinical practice guidelines in oncology in prostate cancer. Version 2. 2013. http:\/\/www.NCCN.org"},{"key":"10.1684\/bdc.2013.1840_bib0060","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors. A randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1684\/bdc.2013.1840_bib0065","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/bjc.1995.502","article-title":"A randomized double-blind comparison for intravenous pamidronate and clodronate in the hypercalcemia of malignancy","volume":"72","author":"Purohit","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1684\/bdc.2013.1840_bib0070","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1840_bib0075","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1684\/bdc.2011.1481","article-title":"Traitements des m\u00e9tastases osseuses du cancer","volume":"99","author":"Gligorov","year":"2012","journal-title":"Bull Cancer"},{"key":"10.1684\/bdc.2013.1840_bib0080","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1684\/bdc.2013.1840_bib0085","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1684\/bdc.2013.1840_bib0090","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1684\/bdc.2013.1840_bib0095","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/jco.2012.30.15_suppl.511","article-title":"Randomized trial of marker-directed versus standard schedule of zoledronic acid for bone metastases from breast cancer","volume":"30","author":"Coleman","year":"2012","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1684\/bdc.2013.1840_bib0100","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ctrv.2011.09.003","article-title":"Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature","volume":"38","author":"Gnant","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1684\/bdc.2013.1840_bib0105","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.clon.2012.10.010","article-title":"Bisphosphonates in the adjuvant treatment of breast cancer","volume":"25","author":"Winter","year":"2013","journal-title":"Clin Oncol"},{"key":"10.1684\/bdc.2013.1840_bib0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejca.2011.10.021","article-title":"The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials","volume":"48","author":"Yan","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1684\/bdc.2013.1840_bib0115","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60 months results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2013.1840_bib0120","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1684\/bdc.2013.1840_bib0125","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2013.1840_bib0130","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1684\/bdc.2013.1840_bib0135","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/annonc\/mds169","article-title":"The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis","volume":"23","author":"Hadji","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2013.1840_bib0140","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1200\/JCO.2010.28.2095","article-title":"Oral bisphosponate use and breast cancer incidence in postmenopausal women","volume":"28","author":"Chlebowski","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1840_bib0145","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/sj.bjc.6605555","article-title":"Bisphosphonate for osteoporosis treatment are associated with reduced breast cancer risk","volume":"102","author":"Newcomb","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1684\/bdc.2013.1840_bib0150","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1200\/JCO.2010.28.1113","article-title":"Use of bisphosphonates and risk of postmenopausal breast cancer","volume":"28","author":"Rennert","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1840_bib0155","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.clbc.2012.04.003","article-title":"Bisphosphonate use and the risk of breast cancer: a meta-analysis of published literature","volume":"12","author":"Liu","year":"2012","journal-title":"Clin Breast Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115301892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115301892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T08:25:07Z","timestamp":1602491107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115301892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0007455115301892"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2013.1840","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}